Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT

Nuclear Medicine Communications

Volumn 33, Issue 6, 2012, Pages 563-570

  Calabria, Ferdinando ^a   Chiaravalloti, Agostino ^b   Di Pietro, Barbara ^b   Grasso, Cristina ^a   Schillaci, Orazio ^a,b  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

18F L dihydroxyphenylalanine; brain metastases; brain tumors; molecular imaging; PET CT; recurrence

Indexed keywords

3' FLUOROTHYMIDINE F 18; CESIUM; DIHYDROXYPHENYLALANINE FLUORINE F 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GERMANIUM; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN METASTASIS; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FALSE NEGATIVE RESULT; GLIOMA; GLUCOSE METABOLISM; HUMAN; METASTASIS; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; REVIEW;

BRAIN NEOPLASMS; DIHYDROXYPHENYLALANINE; FLUORINE RADIOISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 84860837855     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328351d566     Document Type: Review

References (55)

1. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983; 305:137-138. (Pubitemid 14235666)
2. Playford ED, Brooks DI. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev 1992; 4:144-171.
3. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 2004; 11:5-12. (Pubitemid 38174915)
4. 18F-FDOPA: a multiple-target molecule. J Nucl Med 2009; 50:1915-1918.
5. 18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Sem Nucl Med 2007; 37:400-419. (Pubitemid 47505221)
6. 11C]methionine. Eur J Nucl Med Mol Imaging 2003; 30:1561-1567. (Pubitemid 37356125)
7. Melega WP, Hoffman JM, Luxen A, Nissenson CHK, Phelps ME, Barrio JR. The effects of carbidopa on the metabolism of 6-[F-18]fluoro-L-dopa in rats, monkeys and humans. Life Sci 1990; 47:149-157. (Pubitemid 20225971)
8. 18F]fluoro-DOPA metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J Cereb Blood Flow Metab 1991; 11:890-897.
9. 18F]fluoro-L-DOPA: use of 4-O-pivaloyl-L-DOPA as a suitable precursor for routine production. Appl Radial Isot 1993; 44:155-759.
10. 18F]fluoro-L-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging 2003; 30: 1004-1008. (Pubitemid 37086943)
11. 18F]fluoro-LDOPA and its metabolism in vivo-a critical review. Int J Rad Appl Instrum B 1992; 19:149-158.
12. 18F] fluorodopa. Appl Radiat Isot 1988; 39:1203-1206. (Pubitemid 19005339)
13. Luxen A, Barrio JR. Fluorination of substituted veratroles via regioselective mercuration. Tetrahedron Lett 1988; 29:1501-1504.
14. Luxen A, Barrio JR, Bida GT, Satyamurthy N. Regioselective radiofluorination: a simple, high yield synthesis of 6-[F-18]fluorodopa. J Labelled Compds Radiopharm 1996; 23:1066.
15. Lemaire C, Damhaut P, Plenevaux A, Comar D. Enantioselective synthesis of 6-[fluorine-18]-fluoro-L-dopa from no-carrier-added fluorine-18-fluoride. J Nucl Med 1994; 21:1996-2002. (Pubitemid 24376619)
16. 18F]fluoro-L-dopa. Nucl Med Commun 2000; 21:799-802.
17. 18F-FDOPA kinetics in brain tumors. J Nucl Med 2007; 48:1651-1661. (Pubitemid 47572713)
18. 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006; 47:904-911. (Pubitemid 46939941)
19. 18F]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144:885-889. (Pubitemid 12049740)
20. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 1995; 58:250-252.
21. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005; 32:663-671. (Pubitemid 41502970)
22. 18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med 2010; 51:1532-1538.
23. Talbot JN, Kerrou K, Gault N, Gutman F, Grahek D, Touboul E, et al. PET and malignant cerebral tumors. Presse Med 2006; 35:1347-1353. (Pubitemid 44387403)
24. 18F-FDG positron emission tomography/computed tomography (PET/CT) and visual analogue scale (VAS): initial experience. Skeletal Radiol 2011; 40:159-165.
25. Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, et al. Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas. Clin Nucl Med 2009; 34: 878-883.
26. 11C]methionine. Eur J Nucl Med Mol Imaging 2003; 30:1561-1567. (Pubitemid 37356125)
27. Schillaci O, Travascio L, Bolacchi F, Calabria F, Bruni C, Cicciò C, et al. Accuracy of early and delayed FDG PET-CTand of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med 2009; 114:890-906.
28. Lee JW, Kim SK, Lee SM, Moon SH, Kim TS. Detection of hepatic metastases using dual-time-point FDG PET/CT scans in patients with colorectal cancer. Mol Imaging Biol 2011; 13:565-567.
29. Kim DW, Jung SA, Kim CG, Park SA. The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors. Clin Nucl Med 2010; 35:400-403.
30. Horky LL, Hsiao EM,Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol 2011; 103: 137-146.
31. 18F-FDOPA PETas a tool for characterizing brain tumors. Rev Esp Med Nucl 2011; 30:88-93.
32. Wagner HN. Fused image tomography: where do we go from here? J Nucl Med 1999; 40:30-33.
33. Tovi M, Lolja A, Erickson A. MR imaging in cerebral gliomas: tissue component analysis in correlation with histopathology of whole-brain specimens. Acta Radiol 1994; 35:495-505.
34. Knopp EA, Cha S, Johnson G, Mazumdar A, Golfinos JG, Zagzag D, et al. Glial neoplasms: dynamic contrast-enhanced T2-weighted MR imaging. Radiology 1999; 211:791-798. (Pubitemid 29249482)
35. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 2009; 71:242-248.
36. Desclée P, Rommel D, Hernalsteen D, Godfraind C, de Coene B, Cosnard G. Gliomatosis cerebri, imaging findings of 12 cases. J Neuroradiol 2010; 37:148-158.
37. 18F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 2003; 30:1266-1269. (Pubitemid 37205382)
38. Salcman M, Kaplan R. Intracranial tumors in adults. In: Salcman M, editor. Neurology of brain tumors. Baltimore: Lippincott Williams & Wilkins; 1991. pp. 1339-1352.
39. Nicholas MK, Prados MD, Larson DA. Malignant astrocytomas. In: Black PM, Loeffler J, editors. Cancer of the nervous system. London: Blackwell; 1997. pp. 464-491.
40. Nieder C, Grosu AL, Molls MA. Comparison of treatment for recurrent malignant gliomas. Cancer Treat Rev 2000; 26:397-409. (Pubitemid 32094859)
41. Scheck AC, Shapiro JR, Coons SW, Norman SA, Johnson PC. Biological and molecular analysis of a low-grade recurrence of a glioblastoma multiforme. Clin Cancer Res 1996; 2:187-199. (Pubitemid 26042192)
42. Burger PC, Dubois PJ, Schold SC, Smith KR Jr, Odom GL, Crafts DC, et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 1983; 58:159-169. (Pubitemid 13190247)
43. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol 2000; 1:459-468.
44. Stupp R, Dietrich PY, Ostermann-Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20:1375-1382. (Pubitemid 34177445)
45. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303:1323-1329. (Pubitemid 11194457)
46. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280. (Pubitemid 20195640)
47. Halperin EC, Bentel G, Heinz ER, Burger PC. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 1989; 17:1347-1350. (Pubitemid 20028658)
48. Lunsford LD, Martinez AJ, Latchaw RE. Magnetic resonance imaging does not define tumor boundaries. Acta Radiol Suppl 1986; 369:154-156.
49. Levivier M, Becerra A, De Witte O, Brotchi J, Goldman S. Radiation necrosis or recurrence. J Neurosurg 1996; 84:148-149.
50. Walbert T, Mikkelsen T. Recurrent high-grade glioma: a diagnostic and therapeutic challenge. Expert Rev Neurother 2011; 11:509-518.
51. Ostergaard L, Hochberg FH, Rabinov JD, Sorensen AG, Lev M, Kim L, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999; 90:300-305. (Pubitemid 29068132)
52. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42:432-445. (Pubitemid 32207394)
53. 18F]fluorodeoxyglucose PET/CT in primary brain tumors: early experience. Clin Neurol Neurosurg 2011; 113:156-161.
54. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 2010; 51:1198-1205.
55. 11C-methionine positron emission tomography in nontumorous brain lesions. No Shinkei Geka 2010; 38:985-995.